Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Brain tumor, adult: Glioblastoma
Country:  U.S.A.
Trial Type:  Treatment
Results 1-25 of 126 for your search:
Start Over
Light Sedation or Intubated General Anesthesia in Reducing Complications and Length of Hospital Stay in Patients With Brain Cancer Undergoing Craniotomy
Status: Active
Phase: Phase IV
Type: Supportive care, Treatment
Age: 19 and over
Trial IDs: OSU-12161, NCI-2014-01110, 2014C0007, NCT02193568
Temozolomide with or without Veliparib in Treating Patients with Newly Diagnosed Glioblastoma Multiforme
Status: Active
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: A071102, NCI-2014-00616, CALGB-A071102, NCT02152982
P2/3 Randomized Study of Toca 511 & Toca FC Versus SOC in Subjects Undergoing Surgery for Recurrent GBM/AA
Status: Active
Phase: Phase III, Phase II
Type: Treatment
Age: 18 to 75
Trial IDs: Tg 511-15-01, NCI-2015-01577, NCT02414165
A Study of the Effectiveness and Safety of Nivolumab Compared to Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma Patients
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CA209-143, NCI-2014-00328, 2013-003738-34, NCT02017717
A Phase 3, Pivotal Trial of VB-111 Plus Bevacizumab vs. Bevacizumab in Patients With Recurrent Glioblastoma (GLOBE)
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: VB-111-215, NCI-2015-01344, NCT02511405
Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: ICT-107-301, NCI-2015-01811, NCT02546102
Study of Nivolumab Compared to Temozolomide, Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CA209-498, NCI-2016-00144, 2015-003739-37, NCT02617589
Trastuzumab in Treating Leptomeningeal Metastases in Patients with HER2-Positive Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NU 10C03, NCI-2011-00110, STU00040150, STU00040150-MOD0003, NCT01325207
Everolimus and Sorafenib Tosylate in Treating Patients with Recurrent High-Grade Gliomas
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 16-C-0011, NCI-2015-02100, BTTC09-01, P152430, NCT01434602
Bevacizumab, Minocycline Hydrochloride, and Radiation Therapy in Treating Patients with Recurrent Glioma
Status: Active
Phase: Phase II, Phase I
Type: Supportive care, Treatment
Age: 18 and over
Trial IDs: HCI55264, NCI-2012-01118, 55264, NCT01580969
Safety and Efficacy of INC280 and Buparlisib (BKM120) in Patients With Recurrent Gliobastoma
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CINC280X2204, NCI-2014-00156, NCT01870726
Liposomal Rhenium Re 186 in Treating Patients with Recurrent Glioma
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CTRC# 12-02, NCI-2014-00900, 1149367, 1-874640-1, 193831, 20141749, HSC20140450X, NCI-2014-00412, NCT01906385
Dose-Escalation Study of TPI 287 + Avastin Followed by Randomized Study of the Same Versus Avastin for Glioblastoma
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: TPI-287-17, NCI-2014-01453, NCT01933815
Plerixafor after Radiation Therapy and Temozolomide in Treating Patients with Newly Diagnosed High Grade Glioma
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 75
Trial IDs: BRN0023, NCI-2013-02012, 5136, NCT01977677
Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 16 and over
Trial IDs: NLG2102, NCI-2014-02063, NCT02052648
Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: STML-701-0114, NCI-2014-01008, NCT02078648
MK-3475 in Combination with MRI-guided Laser Ablation in Recurrent Malignant Gliomas
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 201501072, NCI-2015-00119, 14-x326, NCT02311582
A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: INCB 24360-204 / ECHO-204, NCI-2015-00040, INCB 24360-204, NCT02327078
Study of Marizomib With Bevacizumab in Subjects With WHO Grade IV Malignant Glioma Followed by a Trial of Single-Agent Marizomib
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MRZ-108, NCI-2015-00711, NCT02330562
Multitargeted Tyrosine Kinase Inhibitor PLX3397 in Treating Younger Patients with Refractory Leukemias or Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 3 to 30
Trial IDs: 15-C-0093, NCI-2015-00457, 150093, P141640, NCT02390752
Radiation Therapy with Temozolomide and Pembrolizumab in Treating Patients with Newly Diagnosed Glioblastoma
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NU 15C01, NCI-2015-00736, 3475-168, 51483, STU00200883, NCT02530502
A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: ACE-ST-209, NCI-2016-00105, NCT02586857
Autologous CMV-Specific Cytotoxic T Cells and Temozolomide in Treating Patients with Glioblastoma
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2014-0899, NCI-2016-00183, NCT02661282
Trial of Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide and BMX-001
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: BMX-HGG-001, NCI-2016-00288, NCT02655601
Safety and Efficacy Study in Recurrent Grade IV Glioma
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: NEO100-01, NCI-2016-00632, NCT02704858
Start Over